Sinovac Biotech

Sinovac Biotech Ltd. girma ( Chinese, Nasdaq  ) wani kamfani ne na likitancin halittu na ƙasar Sin wanda ke mai da hankali kan bincike, haɓakawa, ƙira, da kuma tallata rigakafin da ke ba da kariya ga cututtukan ɗan adam . Kamfanin yana zaune ne a gundumar Haidian, Beijing a kasar Sin. An jera kamfanin akan. NASDAQ amma musayar ta dakatar da cinikin Sinovac a watan Fabrairun 2019 saboda yakin wakili. Kamfanin ya fuskanci binciken cin hanci a China.

 Magungunan rigakafi 
Maganin sayar da Sinovac sun haɗa da CoronaVac ( alurar rigakafin COVID-19 ), Inlive ( alurar rigakafin Enterovirus 71 ), Anflu ( alurar rigakafin mura ), Healive (alurar rigakafin hanta A ), maganin varicella da rigakafin mumps .

 Ci gaban rigakafin COVID-19 
CoronaVac kwayar cuta ce da ba a kunna ta ba ta COVID-19 wacce Sinovac ta kirkira. Ya kasance a cikin gwajin asibiti na Phase III a Brazil, Chile, Indonesia, Philippines, da Turkiyya .

Ya dogara da fasahar gargajiya irin ta BBIBP-CorV da BBV152, in ba haka ba an san su da allurar rigakafin cutar COVID-19 da ba a kunna ba a cikin gwaji na Mataki na III. CoronaVac baya buƙatar daskarewa, kuma duka alluran rigakafi da kayan da za a ƙirƙira sabbin allurai ana iya jigilar su kuma a sanya su cikin firiji a 2-8 °C (36-46 °F), yanayin yanayin da ake kiyaye rigakafin mura.
Wani bincike na haƙiƙa na miliyoyin mutanen Chilean goma da suka karɓi CoronaVac ya gano yana da tasiri 66% akan alamun COVID-19, 88% akan asibiti, 90% akan shigar da ICU, da 86% akan mace-mace. A Brazil, bayan kashi 75% na yawan jama'a a Serrana, São Paulo ya karɓi CoronaVac, sakamakon farko ya nuna mutuwar mutane da kashi 95%, asibitoci da kashi 86%, da alamun alamun cutar da kashi 80%. A Indonesiya, bayanan duniya na gaske daga ma'aikatan kiwon lafiya 128,290 sun nuna kariyar kashi 94% daga kamuwa da cutar ta hanyar allurar, inda ta doke sakamakon gwajin asibiti.

Sakamako na uku daga Turkiyya da aka buga a cikin The Lancet ya nuna ingancin 84% bisa ga mahalarta 10,218 a cikin gwaji. Sakamakon mataki na III daga Brazil a baya ya nuna ingancin kashi 50.7% wajen hana kamuwa da cututtuka da kuma kashi 83.7% yana da tasiri wajen hana cututtuka masu laushi da ke buƙatar magani. Ingancin kamuwa da cututtukan alamomi ya karu zuwa 62.3% tare da tazara na kwanaki 21 ko fiye tsakanin allurai.
Ana amfani da CoronaVac a cikin kamfen ɗin rigakafi a ƙasashe daban-daban na Asiya,  Kudancin Amurka, Arewacin Amurka, da Turai. Ya zuwa Afrilu 2021, Sinovac yana da ikon samar da allurai biliyan biyu a shekara kuma ya ba da jimillar allurai miliyan 600. A halin yanzu ana kera shi a wurare da yawa a China, Brazil, da Masar. A ranar 1 ga Yuni 2021, Hukumar Lafiya ta Duniya (WHO) ta tabbatar da rigakafin don amfani da gaggawa. Sinovac ya rattaba hannu kan yarjejeniyoyin sayayya na allurai miliyan 380 daga COVAX .

 Duba kuma 

 CanSino Biologics
 Sinopharm

 Hanyoyin haɗi na waje 



 Manazarta 

Category:Covid-19